COVID‐19 in patients with hidradenitis suppurativa

Lima, Xinaida Taligare; Cueva, Marta Aparicio; Alora, Maria Beatrice T.

doi:10.1111/bjd.19492

Cited by 15 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been postulated that patients with HS are at higher risk for adverse COVID-19 outcomes; 2 however, this has not been previously demonstrated. Lima et al 3 outcomes. 5 Similarly, our analysis showed that HS patients treated with systemic antibiotics or TNF inhibitors were not at higher risk of COVID-19 complications.…”

mentioning

confidence: 97%

“…Lima et al . 3 conducted a medical records analysis (although without matching) and did not show increased risk of hospitalization, intensive care admission or death due to COVID‐19 in patients with HS versus those without; while Galán et al . 4 reviewed the records of 75 HS patients and observed no severe COVID‐19 cases or deaths in a region heavily affected at the time.…”

mentioning

confidence: 99%

“…It has been postulated that patients with HS are at higher risk for adverse COVID-19 outcomes; 2 however, this has not been previously demonstrated. Lima et al 3 conducted a medical records analysis (although without matching) and did not show increased risk of hospitalization, intensive care admission or death due to COVID-19 in patients with HS versus those without; while Galán et al 4 reviewed the records of 75 HS patients and observed no severe COVID-19 cases or deaths in a region heavily affected at the time. Similarly, in our analysis, outcomes of COVID-19 were not significantly different between patients with and without HS after matching.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Coronavirus disease 2019 complications in patients with hidradenitis suppurativa: A multicenter analysis

Raiker

Pakhchanian

Pham

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

mentioning

confidence: 97%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Coronavirus disease 2019 complications in patients with hidradenitis suppurativa: A multicenter analysis

Raiker

Pakhchanian

Pham

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

“…This suggests that in the case of SARS‐CoV‐2, HS patients are not prone to excessive pro‐inflammatory reaction. Furthermore, among 8000 patients with HS from the United States, only 39 developed COVID‐19 15 …”

Section: Covid‐19 and Hsmentioning

confidence: 99%

Anti‐COVID‐19 measurements for hidradenitis suppurativa patients

Giamarellos‐Bourboulis

Bettoli

Jemec

et al. 2021

Experimental Dermatology

View full text Add to dashboard Cite

The reported incidence of COVID‐19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID‐19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID‐19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti‐COVID‐19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS‐CoV2 and patients affected by metabolic syndrome constitute a high‐risk group for COVID‐19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non‐living virus anti‐SARS‐CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.

show abstract

“…The incidence of COVID‐19 in HS patients is low as reported in several retrospective studies. In a cohort of more than 8000 HS patients in the United States, 2 there were 39 cases of COVID‐19, eight of these were hospitalized due to respiratory complications and one died in intensive care. Interestingly, the majority of these COVID‐19 patients were not treated with systemic therapy for HS and no specific risk factors were identified.…”

mentioning

confidence: 99%